BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33847741)

  • 61. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
    J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
    Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
    J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
    Swerdlow SH
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.
    Davies N; Francis T; Oldreive C; Azam M; Wilson J; Byrd PJ; Burley M; Sharma-Oates A; Keane P; Alatawi S; Higgs MR; Rudzki Z; Ibrahim M; Perry T; Agathanggelou A; Hewitt AM; Smith E; Bonifer C; O'Connor M; Forment JV; Murray PG; Fennell E; Kelly G; Chang C; Stewart GS; Stankovic T; Kwok M; Taylor AM
    Haematologica; 2024 Jun; ():. PubMed ID: 38841800
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
    Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
    Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combined multiomics analysis reveals the mechanism of CENPF overexpression-mediated immune dysfunction in diffuse large B-cell lymphoma
    Yang D; Wang J; Hu M; Li F; Yang F; Zhao Y; Xu Y; Zhang X; Tang L; Zhang X
    Front Genet; 2022; 13():1072689. PubMed ID: 36644760
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
    Best S; Hashiguchi T; Kittai A; Bruss N; Paiva C; Okada C; Liu T; Berger A; Danilov AV
    Blood Adv; 2019 Jan; 3(1):51-62. PubMed ID: 30617217
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
    Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
    [TBL] [Abstract][Full Text] [Related]  

  • 75. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
    Meng H; Zhao B; Wang Y
    Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antitumor Effects of Poplar Propolis on DLBCL SU-DHL-2 Cells.
    Liu X; Tian Y; Yang A; Zhang C; Miao X; Yang W
    Foods; 2023 Jan; 12(2):. PubMed ID: 36673375
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Intervention effects of sodium selenite on DLBCL cell SU-DHL-4 and its mechanism].
    Meng X; Zhang J; Chen KF; Chen H; Yang LJ; Chen JY
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2022 Jul; 38(4):313-316. PubMed ID: 36414553
    [No Abstract]   [Full Text] [Related]  

  • 80. The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia.
    Chang Y; Keramatnia F; Ghate PS; Nishiguchi G; Gao Q; Iacobucci I; Yang L; Chepyala D; Mishra A; High AA; Goto H; Akahane K; Peng J; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
    Blood; 2023 Aug; 142(7):629-642. PubMed ID: 37172201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.